This record was last updated January 7, 2026 (before its estimated July 13, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-02.
Status change: Not Yet Recruiting → Recruiting2026-01-05